Want to see IN:MANKIND full AI Analyst Report?

Mankind Pharma Ltd. (MANKIND) Stock Forecast & Price Target

15 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MANKIND Analyst Ratings

Hold

2 Buy

1 Hold

1 Sell

Based on 4 analysts giving stock ratings to

Mankind

Pharma Ltd.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MANKIND Stock 12 Month Forecast

Average Price Target

₹2,659.25

▲(6.14% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Mankind Pharma Ltd. in the last 3 months. The average price target is ₹2,659.25 with a high forecast of ₹3,220.00 and a low forecast of ₹2,057.00. The average price target represents a 6.14% change from the last price of ₹2,505.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2000":"₹2,000","3221":"₹3,221","2305.25":"₹2,305.3","2610.5":"₹2,610.5","2915.75":"₹2,915.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3220,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹3.22K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2659.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.66K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2057,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.06K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2000,2305.25,2610.5,2915.75,3221],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2469.9,2527.6,2585.3,2643,2700.7000000000003,2758.4,2816.1,2873.8,2931.5,2989.2,3046.9,3104.6,3162.3,{"y":3220,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2469.9,2484.4653846153847,2499.0307692307692,2513.596153846154,2528.1615384615384,2542.726923076923,2557.2923076923075,2571.8576923076926,2586.423076923077,2600.9884615384617,2615.5538461538463,2630.119230769231,2644.6846153846154,{"y":2659.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2469.9,2438.138461538462,2406.376923076923,2374.6153846153848,2342.853846153846,2311.0923076923077,2279.3307692307694,2247.5692307692307,2215.8076923076924,2184.046153846154,2152.2846153846153,2120.523076923077,2088.7615384615383,{"y":2057,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2561.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2518.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2438.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2382.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2229.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2163.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2067.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2244.95,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2001.15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2246.55,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2320.35,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2490.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2469.9,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹3,220

Average Price Target₹2,659

Lowest Price Target₹2,057

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Bansi Desai

J.P. Morgan

₹2,700

Hold

7.77%

Upside

Downgraded

08/04/26

Mankind Pharma Ltd. (MANKIND) was downgraded to a Hold Rating at J.P. Morgan

Alok Dalal

Jefferies

₹3,000→₹3,220

Buy

28.52%

Upside

Reiterated

07/31/26

Jefferies Remains a Buy on Mankind Pharma Ltd. (MANKIND)

Antu Eapan Thomas

Geojit Research

₹2,600→₹2,660

Buy

6.17%

Upside

Reiterated

06/16/26

Hence we revise our stance to ACCUMULATE, with a rolled forward target price of Rs. 2,660, based on 37x FY28E adjusted earnings per share.

Unknown Analyst

Bernstein

Not Ranked

Bernstein

₹2,057

Sell

-17.90%

Downside

Reiterated

06/03/26

Bernstein Keeps Their Sell Rating on Mankind Pharma Ltd. (MANKIND)

Tushar Manudhane

Motilal Oswal

₹2,640

Buy

5.37%

Upside

Reiterated

04/29/26

We value Mankind at 35x 12M forward earnings to arrive at a TP of INR2,640. Reiterate BUY.

Alankar Garude

Kotak Mahindra

₹2,800

Buy

11.76%

Upside

Reiterated

09/29/25

Kotak Mahindra Sticks to Its Buy Rating for Mankind Pharma Ltd. (MANKIND)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Bansi Desai

J.P. Morgan

₹2,700

Hold

7.77%

Upside

Downgraded

08/04/26

Mankind Pharma Ltd. (MANKIND) was downgraded to a Hold Rating at J.P. Morgan

Alok Dalal

Jefferies

₹3,000→₹3,220

Buy

28.52%

Upside

Reiterated

07/31/26

Jefferies Remains a Buy on Mankind Pharma Ltd. (MANKIND)

Antu Eapan Thomas

Geojit Research

₹2,600→₹2,660

Buy

6.17%

Upside

Reiterated

06/16/26

Hence we revise our stance to ACCUMULATE, with a rolled forward target price of Rs. 2,660, based on 37x FY28E adjusted earnings per share.

Unknown Analyst

Bernstein

Not Ranked

Bernstein

₹2,057

Sell

-17.90%

Downside

Reiterated

06/03/26

Bernstein Keeps Their Sell Rating on Mankind Pharma Ltd. (MANKIND)

Tushar Manudhane

Motilal Oswal

₹2,640

Buy

5.37%

Upside

Reiterated

04/29/26

We value Mankind at 35x 12M forward earnings to arrive at a TP of INR2,640. Reiterate BUY.

Alankar Garude

Kotak Mahindra

₹2,800

Buy

11.76%

Upside

Reiterated

09/29/25

Kotak Mahindra Sticks to Its Buy Rating for Mankind Pharma Ltd. (MANKIND)

Stocks with the Highest Top Analyst Consensus in the General Sector

SKHYSK Hynix

ITGITG Inc. Class A

LIMENeutron Holdings, Inc.

EROCERock

CBRSCerebras Systems, Inc. Class A

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mankind Pharma Ltd.

3 Months

Alok DalalJefferies

Success Rate

1/6 ratings generated profit

Average Return

-4.48%

Copying Alok Dalal's trades and holding each position for 3 Months would result in 16.67% of your transactions generating a profit, with an average return of -4.48% per trade.

1 Year

Alok DalalJefferies

Success Rate

1/6 ratings generated profit

Average Return

-5.53%

Copying Alok Dalal's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -5.53% per trade.

2 Years

Alok DalalJefferies

Success Rate

1/6 ratings generated profit

Average Return

-4.82%

Copying Alok Dalal's trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -4.82% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MANKIND Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MANKIND has received 2 Buy Ratings, 1 Hold Ratings, and 2 Sell Ratings. MANKIND average Analyst price target in the past 3 months is 2,659.25.

Each month's total comprises the sum of three months' worth of ratings.

MANKIND Financial Forecast

MANKIND Earnings Forecast

Next quarter’s earnings estimate for MANKIND is ₹17.05 with a range of ₹16.80 to ₹17.30. The previous quarter’s EPS was ₹13.80. MANKIND beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 49.87% of the time in the same period. In the last calendar year MANKIND has Performed in-line its overall industry.

MANKIND Sales Forecast

Next quarter’s sales forecast for MANKIND is ₹41.72B with a range of ₹41.72B to ₹41.72B. The previous quarter’s sales results were ₹40.31B. MANKIND beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 62.90% of the time in the same period. In the last calendar year MANKIND has Performed in-line its overall industry.

MANKIND Stock Forecast FAQ

What is IN:MANKIND’s average 12-month price target, according to analysts?

Based on analyst ratings, Mankind Pharma Ltd.’s 12-month average price target is 2,659.25.

What is IN:MANKIND’s upside potential, based on the analysts’ average price target?

Mankind Pharma Ltd. has 6.14% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Mankind Pharma Ltd. a Buy, Sell or Hold?

Mankind Pharma Ltd. has a consensus rating of Hold, which is based on 2 buy ratings, 1 hold ratings and 1 sell ratings.

What is Mankind Pharma Ltd.’s share price target?

The average share price target for Mankind Pharma Ltd. is 2,659.25. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹3,220.00 ,and the lowest forecast is ₹2,057.00. The average share price target represents 6.14% Increase from the current price of ₹2,505.4.

What do analysts say about Mankind Pharma Ltd.?

Mankind Pharma Ltd.’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Mankind Pharma Ltd.?

To buy shares of IN:MANKIND, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Mankind Pharma Ltd. (MANKIND) Stock Forecast & Price Target

MANKIND Analyst Ratings

MANKIND Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mankind Pharma Ltd.

MANKIND Analyst Recommendation Trends

MANKIND Financial Forecast

MANKIND Earnings Forecast

MANKIND Sales Forecast

MANKIND Stock Forecast FAQ

Detailed List of Analyst Forecasts